Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions to improve health equity and reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Categories: Health.

More Information